Pleiotropic role for MYCN in medulloblastoma

Genes and Development

Volumn 24, Issue 10, 2010, Pages 1059-1072

  Swartling, Fredrik J ^a   Grimmer, Matthew R ^a   Hackett, Christopher S ^a   Northcott, Paul A ^b   Fan, Qi Wen ^a   Goldenberg, David D ^a   Lau, Jasmine ^a   Masic, Selma ^a   Nguyen, Kim ^a   Yakovenko, Slava ^a   Zhe, Xiao Ning ^a   Flynn Gilmer, Heather C ^c   Collins, Rodney ^a   Nagaoka, Mai ^d   Phillips, Joanna J ^a   Jenkins, Robert B ^c   Tihan, Tarik ^a   Vandenberg, Scott R ^a   James, C David ^a   Tanaka, Kohichi ^d   Taylor, Michael D ^b   Weiss, William A ^a   Chesler, Louis ^e   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c MAYO CLINIC   (United States)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Cerebellum; Large cell anaplastic; Medulloblastoma; N myc; Oncogene addiction; SHH independent

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CORRELATION ANALYSIS; GENE; MEDULLOBLASTOMA; MENINGEAL METASTASIS; MOUSE; MYCN GENE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

AMINO ACID TRANSPORT SYSTEM X-AG; ANIMALS; CELL AGING; CELL CYCLE; CEREBELLUM; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMIC INSTABILITY; HEDGEHOG PROTEINS; HUMANS; MEDULLOBLASTOMA; MICE; MICE, TRANSGENIC; NEOPLASM METASTASIS; NUCLEAR PROTEINS; ONCOGENE PROTEINS;

EPICOCCUM; ERINACEIDAE; MUS MUSCULUS;

EID: 77952375097     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.1907510     Document Type: Article

References (75)

1. Adamson DC, Shi Q, Wortham M, Northcott PA, Di C, Duncan CG, Li J, McLendon RE, Bigner DD, Taylor MD, et al. 2009. OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas. Cancer Res 70: 181-191.
2. Adesina AM, Nalbantoglu J, Cavenee WK. 1994. p53 gene mutation and mdm2 gene amplification are uncommon in medulloblastoma. Cancer Res 54: 5649-5651. (Pubitemid 2158389)
3. Aldosari N, Bigner SH, Burger PC, Becker L, Kepner JL, Friedman HS, McLendon RE. 2002. MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Arch Pathol Lab Med 126: 540-544.
4. Ben-Arie N, Bellen HJ, Armstrong DL, McCall AE, Gordadze PR, Guo Q, Matzuk MM, Zoghbi HY. 1997. Math1 is essential for genesis of cerebellar granule neurons. Nature 390: 169-172. (Pubitemid 27507985)
5. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. 1984. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224: 1121-1124. (Pubitemid 14106392)
6. Browd SR, Kenney AM, Gottfried ON, Yoon JW, Walterhouse D, Pedone CA, Fults DW. 2006. N-myc can substitute for insulin-like growth factor signaling in a mouse model of Sonic hedgehog-induced medulloblastoma. Cancer Res 66: 2666-2672.
7. Brown HG, Kepner JL, Perlman EJ, Friedman HS, Strother DR, Duffner PK, Kun LE, Goldthwaite PT, Burger PC. 2000. 'Large cell/anaplastic' medulloblastomas: A Pediatric Oncology Group Study. J Neuropathol Exp Neurol 59: 857-865.
8. Buhren J, Christoph AH, Buslei R, Albrecht S, Wiestler OD, Pietsch T. 2000. Expression of the neurotrophin receptor p75NTR in medulloblastomas is correlated with distinct histological and clinical features: Evidence for a medulloblastoma subtype derived from the external granule cell layer. J Neuropathol Exp Neurol 59: 229-240.
9. Cai DX, Mafra M, Schmidt RE, Scheithauer BW, Park TS, Perry A. 2000. Medulloblastomas with extensive posttherapy neuronal maturation. Report of two cases. J Neurosurg 93: 330-334. (Pubitemid 30604878)
10. Chesler L, Schlieve C, Goldenberg DD, Kenney A, Kim G, McMillan A, Matthay KK, Rowitch D, Weiss WA. 2006. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res 66: 8139-8146.
11. Clifford SC, Lusher ME, Lindsey JC, Langdon JA, Gilbertson RJ, Straughton D, Ellison DW. 2006. Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle 5: 2666-2670.
12. Coller HA, Grandori C, Tamayo P, Colbert T, Lander ES, Eisenman RN, Golub TR. 2000. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci 97: 3260-3265.
13. Davis FG, McCarthy BJ, Freels S, Kupelian V, Bondy ML. 1999. The conditional probability of survival of patients with primary malignant brain tumors: Surveillance, epidemiology, and end results (SEER) data. Cancer 85: 485-491.
14. de Haas T, Oussoren E, Grajkowska W, Perek-Polnik M, Popovic M, Zadravec-Zaletel L, Perera M, Corte G, Wirths O, van Sluis P, et al. 2006. OTX1 and OTX2 expression correlates with the clinicopathologic classification of medulloblastomas. J Neuropathol Exp Neurol 65: 176-186.
15. Eberhart CG. 2007. In search of the medulloblast: Neural stem cells and embryonal brain tumors. Neurosurg Clin N Am 18: 59-69.
16. Eberhart CG, Burger PC. 2003. Anaplasia and grading in medulloblastomas. Brain Pathol 13: 376-385.
17. Eberhart CG, Kratz JE, Schuster A, Goldthwaite P, Cohen KJ, Perlman EJ, Burger PC. 2002. Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas. Brain Pathol 12: 36-44. (Pubitemid 33131360)
18. Eberhart CG, Kratz J, Wang Y, Summers K, Stearns D, Cohen K, Dang CV, Burger PC. 2004. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 63: 441-449. (Pubitemid 38669665)
19. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ, Hancock DC. 1992. Induction of apoptosis in fibroblasts by c-myc protein. Cell 69: 119-128.
20. Finlay JL, Erdreich-Epstein A, Packer RJ. 2007. Progress in the treatment of childhood brain tumors: No room for complacency. Pediatr Hematol Oncol 24: 79-84.
21. Furuta A, Rothstein JD, Martin LJ. 1997. Glutamate transporter protein subtypes are expressed differentially during rat CNS development. J Neurosci 17: 8363-8375. (Pubitemid 27461059)
22. Gajjar A, Hernan R, Kocak M, Fuller C, Lee Y, McKinnon PJ, Wallace D, Lau C, Chintagumpala M, Ashley DM, et al. 2004. Clinical, histopathologic, and molecular markers of prognosis: Toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 22: 984-993.
23. Gilbertson RJ. 2004. Medulloblastoma: Signalling a change in treatment. Lancet Oncol 5: 209-218.
24. Goodrich LV, Milenkovic L, Higgins KM, Scott MP. 1997. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 277: 1109-1113. (Pubitemid 27371635)
25. Gossen M, Bujard H. 1992. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci 89: 5547-5551.
26. Grimmer MR, Weiss WA. 2008. BMPs oppose Math1 in cerebellar development and in medulloblastoma. Genes & Dev 22: 693-699.
27. Hackett CS, Hodgson JG, Law ME, Fridlyand J, Osoegawa K, de Jong PJ, Nowak NJ, Pinkel D, Albertson DG, Jain A, et al. 2003. Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors. Cancer Res 63: 5266-5273.
28. Hallahan AR, Pritchard JI, Hansen S, Benson M, Stoeck J, Hatton BA, Russell TL, Ellenbogen RG, Bernstein ID, Beachy PA, et al. 2004. The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res 64: 7794-7800.
29. Hatton BA, Knoepfler PS, Kenney AM, Rowitch DH, de Alboran IM, Olson JM, Eisenman RN. 2006. N-myc is an essential downstream effector of Shh signaling during both normal and neoplastic cerebellar growth. Cancer Res 66: 8655-8661.
30. Hatton BA, Villavicencio EH, Tsuchiya KD, Pritchard JI, Ditzler S, Pullar B, Hansen S, Knoblaugh SE, Lee D, Eberhart CG, et al. 2008. The Smo/Smo model: Hedgehog-induced medulloblastoma with 90% incidence and leptomeningeal spread. Cancer Res 68: 1768-1776.
31. Hogarty MD, Norris MD, Davis K, Liu X, Evageliou NF, Hayes CS, Pawel B, Guo R, Zhao H, Sekyere E, et al. 2008. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Cancer Res 68: 9735-9745.
32. Hsieh PC, Wu CT, Lin KL, Jaing TH, Tseng CK, Lui TN, Jung SM. 2008. The clinical experience of medulloblastoma treatment and the significance of time sequence for development of leptomeningeal metastasis. Childs Nerv Syst 24: 1463-1467.
33. Jain AN, Tokuyasu TA, Snijders AM, Segraves R, Albertson DG, Pinkel D. 2002. Fully automatic quantification of microarray image data. Genome Res 12: 325-332.
34. Johansson FK, Goransson H, Westermark B. 2005. Expression analysis of genes involved in brain tumor progression driven by retroviral insertional mutagenesis in mice. Oncogene 24: 3896-3905.
35. Johnson RL, Rothman AL, Xie J, Goodrich LV, Bare JW, Bonifas JM, Quinn AG, Myers RM, Cox DR, Epstein EH Jr, et al. 1996. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 272: 1668-1671.
36. Kane W, Aronson SM. 1967. Gangliogliomatous maturation in cerebellar medulloblastoma. Acta Neuropathol 9: 273-279.
37. Kenney AM, Cole MD, Rowitch DH. 2003. Nmyc upregulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neuron precursors. Development 130: 15-28.
38. Kessler JD, Hasegawa H, Brun SN, Yang ZJ, Dutton JW, Wang F, Wechsler-Reya RJ. 2009. N-myc alters the fate of preneoplastic cells in a mouse model of medulloblastoma. Genes & Dev 23: 157-170.
39. Knoepfler PS, Cheng PF, Eisenman RN. 2002. N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation. Genes & Dev 16: 2699-2712.
40. Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P, Troost D, Meeteren NS, Caron HN, Cloos J, et al. 2008. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 3: e3088. doi: 10.1371/journal.pone. 0003088.
41. Kraus JA, Koch A, Albrecht S, Von Deimling A, Wiestler OD, Pietsch T. 1996. Loss of heterozygosity at locus F13B on chromosome 1q in human medulloblastoma. Int J Cancer 67: 11-15. (Pubitemid 26236061)
42. Kudo M, Shimizu M, Akutsu Y, Imaya H, Chen MN, Miura M. 1990. Ganglioglial differentiation in medulloblastoma. Acta Pathol Jpn 40: 50-56.
43. Lee Y, Miller HL, Jensen P, Hernan R, Connelly M, Wetmore C, Zindy F, Roussel MF, Curran T, Gilbertson RJ, et al. 2003. A molecular fingerprint for medulloblastoma. Cancer Res 63: 5428-5437.
44. Leonard JR, Cai DX, Rivet DJ, Kaufman BA, Park TS, Levy BK, Perry A. 2001. Large cell/anaplastic medulloblastomas and medullomyoblastomas: Clinicopathological and genetic features. J Neurosurg 95: 82-88.
45. Li H, Wang B, Yang A, Lu R, Wang W, Zhou Y, Shi G, Kwon SW, Zhao Y, Jin Y. 2009. Ly-1 antibody reactive clone is an important nucleolar protein for control of self-renewal and differentiation in embryonic stem cells. Stem Cells 27: 1244-1254.
46. Machold R, Fishell G. 2005. Math1 is expressed in temporally discrete pools of cerebellar rhombic-lip neural progenitors. Neuron 48: 17-24.
47. Mao J, Ligon KL, Rakhlin EY, Thayer SP, Bronson RT, Rowitch D, McMahon AP. 2006. A novel somatic mouse model to survey tumorigenic potential applied to the Hedgehog pathway. Cancer Res 66: 10171-10178.
48. McCall TD, Pedone CA, Fults DW. 2007. Apoptosis suppression by somatic cell transfer of Bcl-2 promotes Sonic hedgehog-dependent medulloblastoma formation in mice. Cancer Res 67: 5179-5185.
49. McManamy CS, Lamont JM, Taylor RE, Cole M, Pearson AD, Clifford SC, Ellison DW. 2003. Morphophenotypic variation predicts clinical behavior in childhood non-desmoplastic medulloblastomas. J Neuropathol Exp Neurol 62: 627-632.
50. Momota H, Shih AH, Edgar MA, Holland EC. 2008. c-Myc and β-catenin cooperate with loss of p53 to generate multiple members of the primitive neuroectodermal tumor family in mice. Oncogene 27: 4392-4401.
51. Nesbit CE, Grove LE, Yin X, Prochownik EV. 1998. Differential apoptotic behaviors of c-myc, N-myc, and L-myc oncoproteins. Cell Growth Differ 9: 731-741.
52. Northcott PA, Fernandez LA, Hagan JP, Ellison DW, Grajkowska W, Gillespie Y, Grundy R, Van Meter T, Rutka JT, Croce CM, et al. 2009. The miR-17/92 polycistron is up-regulated in Sonic hedgehog-driven medulloblastomas and induced by N-myc in Sonic hedgehog-treated cerebellar neural precursors. Cancer Res 69: 3249-3255.
53. Oliver TG, Grasfeder LL, Carroll AL, Kaiser C, Gillingham CL, Lin SM, Wickramasinghe R, Scott MP, Wechsler-Reya RJ. 2003. Transcriptional profiling of the Sonic hedgehog response: A critical role for N-myc in proliferation of neuronal precursors. Proc Natl Acad Sci 100: 7331-7336.
54. Pfister S, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J, Wittmann A, Devens F, Gerber NU, Joos S, et al. 2009. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol 27: 1627-1636.
55. Polkinghorn WR, Tarbell NJ. 2007. Medulloblastoma: Tumorigenesis, current clinical paradigm, and efforts to improve risk stratification. Nat Clin Pract Oncol 4: 295-304.
56. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, Kim JY, Goumnerova LC, Black PM, Lau C, et al. 2002. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415: 436-442.
57. Preusser M, Laggner U, Haberler C, Heinzl H, Budka H, Hainfellner JA. 2006. Comparative analysis of NeuN immunoreactivity in primary brain tumours: Conclusions for rational use in diagnostic histopathology. Histopathology 48: 438-444.
58. Raffel C, Jenkins RB, Frederick L, Hebrink D, Alderete B, Fults DW, James CD. 1997. Sporadic medulloblastomas contain PTCH mutations. Cancer Res 57: 842-845.
59. Rao G, Pedone CA, Del Valle L, Reiss K, Holland EC, Fults DW. 2004. Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice. Oncogene 23: 6156-6162.
60. Rogers HA, Miller S, Lowe J, Brundler MA, Coyle B, Grundy RG. 2009. An investigation of WNT pathway activation and association with survival in central nervous system primitive neuroectodermal tumours (CNS PNET). Br J Cancer 100: 1292-1302.
61. Sawai S, Shimono A, Wakamatsu Y, Palmes C, Hanaoka K, Kondoh H. 1993. Defects of embryonic organogenesis resulting from targeted disruption of the N-myc gene in the mouse. Development 117: 1445-1455.
62. Schuller U, Heine VM, Mao J, Kho AT, Dillon AK, Han YG, Huillard E, Sun T, Ligon AH, Qian Y, et al. 2008. Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. Cancer Cell 14: 123-134.
63. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, Hammond D. 1985. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313: 1111-1116.
64. Shakhova O, Leung C, van Montfort E, Berns A, Marino S. 2006. Lack of Rb and p53 delays cerebellar development and predisposes to large cell anaplastic medulloblastoma through amplification of N-Myc and Ptch2. Cancer Res 66: 5190-5200.
65. Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A, Shohet JM. 2005. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci 102: 731-736.
66. Stearns D, Chaudhry A, Abel TW, Burger PC, Dang CV, Eberhart CG. 2006. c-myc overexpression causes anaplasia in medulloblastoma. Cancer Res 66: 673-681.
67. Su L, Hershberger RJ, Weissman IL. 1993. LYAR, a novel nucleolar protein with zinc finger DNA-binding motifs, is involved in cell growth regulation. Genes & Dev 7: 735-748.
68. Takei H, Nguyen Y, Mehta V, Chintagumpala M, Dauser RC, Adesina AM. 2009. Low-level copy gain versus amplification of myc oncogenes in medulloblastoma: Utility in predicting prognosis and survival. Laboratory investigation. J Neurosurg Pediatr 3: 61-65.
69. Tanaka K, Watase K, Manabe T, Yamada K, Watanabe M, Takahashi K, Iwama H, Nishikawa T, Ichihara N, Kikuchi T, et al. 1997. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 276: 1699-1702.
70. Thomas WD, Chen J, Gao YR, Cheung B, Koach J, Sekyere E, Norris MD, Haber M, Ellis T, Wainwright B, et al. 2009. Patched1 deletion increases N-Myc protein stability as a mechanism of medulloblastoma initiation and progression. Oncogene 28: 1605-1615.
71. Uziel T, Zindy F, Xie S, Lee Y, Forget A, Magdaleno S, Rehg JE, Calabrese C, Solecki D, Eberhart CG, et al. 2005. The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation. Genes & Dev 19: 2656-2667.
72. Wang VY, Rose MF, Zoghbi HY. 2005. Math1 expression redefines the rhombic lip derivatives and reveals novel lineages within the brainstem and cerebellum. Neuron 48: 31-43.
73. Wetmore C, Eberhart DE, Curran T. 2001. Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. Cancer Res 61: 513-516.
74. Yang ZJ, Ellis T, Markant SL, Read TA, Kessler JD, Bourboulas M, Schuller U, Machold R, Fishell G, Rowitch DH, et al. 2008. Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells. Cancer Cell 14: 135-145.
75. Zindy F, Uziel T, Ayrault O, Calabrese C, Valentine M, Rehg JE, Gilbertson RJ, Sherr CJ, Roussel MF. 2007. Genetic alterations in mouse medulloblastomas and generation of tumors de novo from primary cerebellar granule neuron precursors. Cancer Res 67: 2676-2684.